E-Signature Compliance Insights

March 13, 202610 min read

Audit Trails in Regulated Industries: Complete Guide

An audit trail is a secure, computer-generated record of who did what, when, and why in a regulated system. This guide covers FDA 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11, hash chain verification, common 483 findings, and implementation best practices.

March 11, 202611 min read

DocuSign Part 11 Module vs Purpose-Built Compliance Platforms

DocuSign addresses FDA 21 CFR Part 11 through a paid add-on module. Purpose-built platforms embed compliance controls natively. This guide compares the two architectures across audit trails, 2FA, validation burden, total cost of ownership, and organizational fit for life sciences.

March 11, 202612 min read

How to Validate an E-Signature System: IQ/OQ/PQ Under CSA

Learn how to validate an e-signature system using IQ/OQ/PQ under FDA's 2025 Computer Software Assurance (CSA) guidance. Covers risk-based testing, Part 11 mapping, qualification checklists, change control, and common validation pitfalls for pharma, biotech, and medical device companies.

21 CFR Part 11 E-Signature Vendor Selection Checklist: RFP Template & Evaluation Criteria

A comprehensive, regulation-referenced vendor selection checklist for evaluating 21 CFR Part 11 compliant e-signature platforms. Covers Subpart B and C requirements, audit trail criteria, security controls, infrastructure qualification, scoring framework, and red flags — ready to use as an RFP template.

FDA Warning Letters & Data Integrity: Lessons from Real Enforcement Actions

Data integrity deficiencies appear in 60-80% of FDA drug GMP warning letters. This guide examines real warning letters citing shared logins, missing audit trails, backdated records, and absent training — with consequences including consent decrees, import bans, and criminal prosecution.

March 11, 202611 min read

Clinical Trials

Decentralized Clinical Trials & eConsent: E-Signature Requirements

Decentralized clinical trials (DCTs) use telehealth and direct-to-patient technologies for remote trial conduct. This guide covers the FDA's September 2024 DCT guidance, eConsent best practices, e-signature compliance under Part 11 and ICH E6(R3), and data integrity for remote workflows.

March 11, 202612 min read

How to Migrate to a Part 11 E-Signature Platform: 6-Phase Framework

Migrating from paper or legacy systems to a 21 CFR Part 11 compliant e-signature platform requires structured change control. This guide covers a six-phase migration framework: requirements, validation, pilot, parallel running, cutover, and decommission — with audit trail continuity and training strategies.

Medical Device E-Signatures Under QMSR, ISO 13485 & EU MDR

The FDA's QMSR replaced the QSR on February 2, 2026, incorporating ISO 13485:2016 by reference. This guide covers how e-signatures interact with the new QMSR, Part 11's independent requirements, EU MDR documentation obligations, and validation strategies for dual-market medical device companies.

AI & Electronic Signatures in Regulated Industries: Compliance Guide

AI is transforming e-signature workflows in life sciences — from intelligent document routing to anomaly detection and predictive compliance. This guide covers the FDA's AI guidance, EU AI Act high-risk classification, Part 11 implications, and a risk-based framework for adopting AI-enhanced compliance tools.

CSV vs CSA: Computer System Validation vs Software Assurance Explained

FDA's Computer Software Assurance (CSA) guidance, finalized September 2025, replaces traditional CSV with risk-based validation. This guide compares CSV and CSA approaches, explains risk classification for e-signature functions, and provides practical transition strategies for life sciences organizations.

EU GMP Annex 11 (2025 Draft): Computerized Systems Compliance Guide

The 2025 draft revision of EU GMP Annex 11 expands from 5 to 19 pages, adding provisions for AI, cybersecurity, cloud/SaaS, and enhanced e-signature requirements including multi-factor authentication and eIDAS alignment. This guide covers key changes, FDA Part 11 comparison, and preparation strategies.

March 10, 202611 min read

How to Choose an E-Signature Platform for Life Sciences

Evaluating e-signature platforms for pharma, biotech, and medical devices? This guide covers FDA 21 CFR Part 11 compliance, audit trail capabilities, 2FA requirements, validation documentation, red flags to avoid, and total cost of ownership for regulated industries.

Healthcare

HIPAA-Compliant Electronic Signatures: Requirements Guide

HIPAA allows electronic signatures but requires BAAs, encryption (AES-256), audit controls, and MFA for documents containing PHI. This guide covers Security Rule safeguards, BAA requirements, audit trails, and best practices for healthcare organizations.

March 6, 20269 min read

eIDAS vs ESIGN Act: Complete Comparison Guide (2026)

The EU eIDAS Regulation defines three signature tiers (SES, AES, QES) while the US ESIGN Act is technology-neutral with a single tier. This guide compares legal frameworks, cross-border recognition, eIDAS 2.0 changes, and compliance strategies for multinational organizations.

March 3, 20269 min read

February 28, 202610 min read

GxP Compliance for Electronic Records: GLP, GMP, GCP Guide

GxP compliance requires electronic records to be attributable, immutable, and audit-trailed. This guide covers GLP, GMP, GCP, GDP, and GVP requirements, ALCOA+ principles, EU Annex 11, system validation (IQ/OQ/PQ), and best practices for life sciences.

Clinical Trials

Electronic Signatures in Clinical Trials: FDA & EU Guide

Electronic signatures in clinical trials must comply with FDA 21 CFR Part 11, EU CTR 536/2014, and ICH E6(R2) GCP. This guide covers regulatory requirements, document types requiring signatures, implementation best practices, and audit readiness strategies.

February 25, 202611 min read